BACKGROUND: AKT (AKT1, AKT2, and AKT3) was a downstream effector of phosphatidylinositide-3-kinase (PI3K) and played crucial roles in protein synthesis, cellular metabolism, survival, and proliferation. The PI3K/AKT pathway was commonly activated in human cancers and was recognized as a potential target for anticancer therapy. Nonetheless, clinical, molecular, or prognostic features of AKT-activated colon cancer remained uncertain. METHODS: Using a database of 717 colon and rectal cancers in the Nurses' Health Study and the Health Professionals Follow-up Study, Ser473 phosphorylated AKT (p-AKT) expression was detected in 448 (62%) tumors by immunohistochemistry. Cox proportional hazards model was used to compute mortality hazards ratio (HR), adjusting for clinical and tumoral features, including PIK3CA, KRAS, BRAF, microsatellite instability (MSI), CpG island methylator phenotype (CIMP), LINE-1 methylation, TP53 (p53), and FASN (fatty acid synthase). RESULTS: Tumor p-AKT expression was associated with PIK3CA mutation (odds ratio [OR], 1.77; 95% confidence interval [CI], 1.12-2.80; P = .015). p-AKT expression was significantly associated with longer colorectal cancer-specific survival in Kaplan-Meier analysis (log-rank P = .0005), univariate Cox regression (HR, 0.62; 95% CI, 0.47-0.82; P = .0006) and multivariate analysis (adjusted HR, 0.75; 95% CI, 0.56-0.99; P = .048) adjusting for clinical and molecular variables including PIK3CA, MSI, CIMP and LINE-1 hypomethylation. p-AKT expression was inversely associated with high stage (III-IV) (adjusted OR, 0.63; 95% CI, 0.45-0.88, P = .0071). CONCLUSIONS: p-AKT expression in colorectal cancer is associated with low stage and good prognosis. p-AKT may serve as a tissue biomarker to identify patients with superior prognosis and a possible therapeutic target (analogous to estrogen receptor ESR1 in breast cancer).
BACKGROUND:AKT (AKT1, AKT2, and AKT3) was a downstream effector of phosphatidylinositide-3-kinase (PI3K) and played crucial roles in protein synthesis, cellular metabolism, survival, and proliferation. The PI3K/AKT pathway was commonly activated in humancancers and was recognized as a potential target for anticancer therapy. Nonetheless, clinical, molecular, or prognostic features of AKT-activated colon cancer remained uncertain. METHODS: Using a database of 717 colon and rectal cancers in the Nurses' Health Study and the Health Professionals Follow-up Study, Ser473 phosphorylated AKT (p-AKT) expression was detected in 448 (62%) tumors by immunohistochemistry. Cox proportional hazards model was used to compute mortality hazards ratio (HR), adjusting for clinical and tumoral features, including PIK3CA, KRAS, BRAF, microsatellite instability (MSI), CpG island methylator phenotype (CIMP), LINE-1 methylation, TP53 (p53), and FASN (fatty acid synthase). RESULTS:Tumor p-AKT expression was associated with PIK3CA mutation (odds ratio [OR], 1.77; 95% confidence interval [CI], 1.12-2.80; P = .015). p-AKT expression was significantly associated with longer colorectal cancer-specific survival in Kaplan-Meier analysis (log-rank P = .0005), univariate Cox regression (HR, 0.62; 95% CI, 0.47-0.82; P = .0006) and multivariate analysis (adjusted HR, 0.75; 95% CI, 0.56-0.99; P = .048) adjusting for clinical and molecular variables including PIK3CA, MSI, CIMP and LINE-1 hypomethylation. p-AKT expression was inversely associated with high stage (III-IV) (adjusted OR, 0.63; 95% CI, 0.45-0.88, P = .0071). CONCLUSIONS: p-AKT expression in colorectal cancer is associated with low stage and good prognosis. p-AKT may serve as a tissue biomarker to identify patients with superior prognosis and a possible therapeutic target (analogous to estrogen receptorESR1 in breast cancer).
Authors: Daniel Buergy; Tina Fuchs; Patryk Kambakamba; Giridhar Mudduluru; Gabriele Maurer; Stefan Post; Yi Tang; Marian T Nakada; Li Yan; Heike Allgayer Journal: Cancer Date: 2009-10-15 Impact factor: 6.860
Authors: Seon Young Nam; Hye Seung Lee; Gyung-Ah Jung; Jimi Choi; Sung Jin Cho; Min Kyu Kim; Woo Ho Kim; Byung Lan Lee Journal: APMIS Date: 2003-12 Impact factor: 3.205
Authors: Robert Farkas; Eva Pozsgai; Andrew V Schally; Andras Szigeti; Edit Szigeti; Zoltan Laszlo; Andras Papp; Eva Gomori; Laszlo Mangel; Peter O Horvath; Szabolcs Bellyei Journal: J Cancer Res Clin Oncol Date: 2011-12-08 Impact factor: 4.553
Authors: Tingting Li; Xiaoyun Liao; Paul Lochhead; Teppei Morikawa; Mai Yamauchi; Reiko Nishihara; Kentaro Inamura; Sun A Kim; Kosuke Mima; Yasutaka Sukawa; Aya Kuchiba; Yu Imamura; Yoshifumi Baba; Kaori Shima; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Shuji Ogino; Zhi Rong Qian Journal: Ann Surg Oncol Date: 2014-07-15 Impact factor: 5.344
Authors: Xiaoyun Liao; Paul Lochhead; Reiko Nishihara; Teppei Morikawa; Aya Kuchiba; Mai Yamauchi; Yu Imamura; Zhi Rong Qian; Yoshifumi Baba; Kaori Shima; Ruifang Sun; Katsuhiko Nosho; Jeffrey A Meyerhardt; Edward Giovannucci; Charles S Fuchs; Andrew T Chan; Shuji Ogino Journal: N Engl J Med Date: 2012-10-25 Impact factor: 91.245
Authors: Liang Wang; Chun-Han Lo; Xiaosheng He; Dong Hang; Molin Wang; Kana Wu; Andrew T Chan; Shuji Ogino; Edward L Giovannucci; Mingyang Song Journal: Gastroenterology Date: 2020-04-01 Impact factor: 22.682
Authors: Jean M Butte; Javiera Torres; Emanuela F Veras; Kenichi Matsuo; Mithat Gönen; Michael I D'Angelica; Enrique Waugh; Manuel Meneses; Yoshiyaki Inayama; Yuman Fong; Ronald P Dematteo; Hernan De La Fuente; Itaru Endo; David S Klimstra; William R Jarnagin Journal: Ann Surg Oncol Date: 2012-12-01 Impact factor: 5.344